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Abstract Pompe disease is a lysosomal storage disorder
characterized by progressive muscle weakness. With the
emergence of new treatment options, psychometrically
robust outcome measures are needed to monitor patients’
clinical status. We constructed a motor function test that is
easy and quick to use. The Quick Motor Function Test
(QMFT) was constructed on the basis of the clinical
expertise of several physicians involved in the care of
Pompe patients; the Gross Motor Function Measure and the
IPA/Erasmus MC Pompe survey. The test comprises 16
items. Validity and test reliability were determined in a
cohort of 91 Pompe patients (5 to 76 years of age). In
addition, responsiveness of the scale to changes in clinical
condition over time was examined in a subgroup of 18
patients receiving treatment and 23 untreated patients.
Interrater and intrarater reliabilities were good (intraclass
correlation coefficients: 0.78 to 0.98 and 0.76 to 0.98). The
test correlated strongly with proximal muscle strength
assessed by hand held dynamometry and manual muscle
testing (rs=0.81, rs=0.89), and showed significant differences
between patient groups with different disease severities. A
clinical-empirical exploration to assess responsiveness
showed promising results, albeit it should be repeated in a
larger group of patients. In conclusion, the Quick Motor
Function Test can reliably rate clinical severity and motor
function in children and adults with Pompe disease.
Introduction
Pompe disease (OMIM #232300) is a rare neuromuscular
disorder caused by deficiency of the lysosomal enzyme acid α-
glucosidase.This deficiency induces glycogen to accumulate in
the lysosomes of many tissues, albeit mainly in skeletal muscle.
Its major clinical manifestation is progressive muscle weak-
ness, which eventually impairs motor and respiratory function
(van der Ploeg and Reuser 2008; Engel and Hirschhorn 1994).
The disease manifests across a spectrum of severity, and
affects infants, children and adults (van den Hout et al. 2003;
Winkel et al. 2005;K i s h n a n ie ta l .2006). Patients with the
classic infantile form present with severe generalized hypoto-
nia and a hypertrophic cardiomyopathy shortly after birth; the
disease progresses rapidly, and the patients usually die in their
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DOI 10.1007/s10545-011-9388-3first year of life from cardiorespiratory failure. Childhood,
juvenile, and adult forms of the disease are characterized by a
more slowly progressive proximal myopathy. Respiratory
muscles are affected as well. In these patients, onset of
symptoms, disease severity and rate of disease progression
varies. Cardiomyopathy rarely occurs. The majority of
patients eventually become wheelchair and respirator-
dependent (Hagemans et al. 2006; Laforet et al. 2000; Wokke
et al. 1995).
In our centre we follow more than 100 children and
adults with Pompe disease. The disease severity of these
patients shows large differences. Some are ambulant and
others completely wheelchair dependent. Currently there is
no functional scale that has been standardized for Pompe
disease and is capable to rate differences in muscle function
sufficiently. This has become even more important since
marketing approval was given to recombinant human
alpha-glucosidase as enzyme replacement therapy for
Pompe disease.
The aim of the present study was to construct a
functional motor scale specific for Pompe disease that is
easy to apply and sufficiently sensitive to assess disease
severity and to detect clinically important changes over
time, so that it can be used both in clinical practice to
monitor disease progression and to evaluate therapeutic
effectiveness. For this purpose, we constructed and psy-
chometrically tested the scale in a large cohort of children
and adults with Pompe disease.
Methods
Construction of the test
Motor function items that were difficult specifically for
patients with Pompe disease were derived from the clinical
expertise of several neurologists, paediatricians, and phys-
ical therapists involved in the treatment and care of Pompe
patients; the Gross Motor Function Measure (Russell et al.
1989), an 88-item motor function test that has been
validated for Cerebral Palsy; and the IPA/Erasmus MC
Pompe survey, an international questionnaire study per-
formed in over 300 Pompe patients (Hagemans et al. 2005;
Hagemans et al. 2007).
The final version of the test consisted of 16 items and
was named the Quick Motor Function Test (Supplement 1).
Administering this test takes approximately 10 to 15
minutes. An evaluator observes the performance of a
patient and scores the items separately on a 5-point ordinal
scale (ranging from 0 to 4). If items can be performed on
both left and right extremities, the right side is taken. A
total score is obtained by adding the scores of all items. The
total score ranges between 0 and 64 points.
Psychometric testing
Subjects
A total of 91 child and adult patients with Pompe disease
who had attended the Erasmus Medical Center between
February 2005 and February 2008 were included in the
present study. All patients were diagnosed with Pompe
disease through the measurement of acid α-glucosidase
activity in cultured fibroblasts or leukocytes, and mutation
analysis. They were enrolled in either one of two observa-
tional studies. One study investigated the rate of disease
progression in untreated patients; the other study monitored
the disease course after start of treatment with recombinant
human alpha-glucosidase. Both studies were approved by the
Institutional Review Board of the Erasmus MC. All patients
(and/or parents if necessary) gave signed informed consent.
Design
In both studies, the newly constructed Quick Motor
Function Test (QMFT) was part of a standardized follow-
up protocol. The following assessments were performed at
baseline and every 3 months thereafter: hand-held dyna-
mometry (HHD) (van der Ploeg 1992; Beenakker et al.
2001), manual muscle testing (MMT) (Brooke et al. 1981),
pulmonary function testing in sitting and supine position
(ATS/ERS Statement on respiratory muscle testing 2002),
and the QMFT. A physical examination was performed at
every visit.
The QMFT was administered by two pediatricians and
two neurologists. Beforehand, all physicians were trained
by testing at least five patients following standardized
instructions, while being observed by one of the senior
physicians who originally developed the test. The test was
performed in a separate examination room and all assess-
ments were videotaped. The scores were recorded on an
QMFT scoring sheet.
Reliability
The internal consistency (Nunnally 1978) was measured by
Cronbach’s α. To estimate intrarater reliability (Hobart et al.
1996), three evaluators were shown the videotapes of the
baseline assessments of 20 of their patients more than one
year after the assessments and were asked to rescore the
QMFT. The patients were randomly selected and the
evaluators were blinded for their initial scoring.
To measure the interrater reliability (Hobart et al. 1996),
videotapes of assessments from 60 randomly selected
patients were scored by all four evaluators.
Test-retest reliability (Hobart et al. 1996) was assessed in
24 patients. As we assumed that little change in functional
318 J Inherit Metab Dis (2012) 35:317–323performance had occurred in this period of time, each
patient was evaluated at baseline and approximately three
months thereafter. The evaluators had no access to their
initial scoring.
Validity
Validity is defined as the extent to which an instrument
measures the concept it is intended to measure (Hobart et
al. 1996). If no gold standard exists to compare the
instrument, criterion validity (Nunnally 1978, Cronbach
and Meehl 1955) may be assessed. Since Pompe disease
predominantly presents as a proximal myopathy, we
examined whether the QMFT would correlate with other
tests that are used to measure proximal muscle weakness.
For this purpose, the strength of proximal muscle groups as
assessed by both manual muscle testing (Brooke et al.
1981) and hand held dynamometry (van der Ploeg 1992,
Beenakker et al. 2001) were compared with the QMFT
score. The following proximal muscle groups were tested:
neck flexors, shoulder abductors, elbow flexors, elbow
extensors, hip flexors, hip abductors, knee extensors, and
knee flexors. To demonstrate that the QMFT score correlat-
ed less well with the strength of other muscles, the
following muscle groups were tested and compared with
the QMFT: neck extensors, wrist extensors, wrist flexors,
foot dorsal flexors, and foot plantar flexors. Finally,
differential validity was assessed by comparing the QMFT
scores of patients with different severities of disease. To this
end, the patients were classified into three groups based on
their ability to walk: patients who were completely
ambulant, patients who were able to walk with aids, and
patients who were completely wheelchair bound.
Responsiveness
To assess the responsiveness of the QMFT, a clinical-
empirical exploration was performed. This analysis includ-
ed a sub-sample of 18 patients who had been treated with
recombinant human α-glucosidase for more than one year,
and also a sub-sample of 23 untreated patients who were
followed for more than one year. As no gold standard
exists, several strategies for assessing responsiveness have
been suggested (Husted et al. 2000; Wright and Young
1997;L i a n g1995). We therefore used three different
methods to explore the responsiveness of the QMFT.
First, we compared the change in score at 12 months
follow-up between the untreated and the treated group.
Second, we calculated sensitivity to change using the
standardized response mean (Wright and Young 1997; Liang
et al. 1990), an effect size statistic that is equal to the mean of
the change in score of treated patients divided by the
standard deviation of the change score. Third, two physicians
were asked to judge whether the motor function of individual
patients in the treated group had to their opinion improved,
remained stable, or deteriorated after 12 months of treatment
(Liang 1995, Deyo and Centor 1986). These physicians were
involved in the care of either children or adults with Pompe
disease but had not participated in the construction and
administration of the QMFT.
Statistical analysis
All continuous variables are described as mean±standard
deviation, or as median and range; categorical data are
presented as percentages. Internal consistency of the test
was measured using Cronbach’s α. A Cronbach’s α>0.80
was considered good. Intrarater reliability, interrater reli-
ability, and test-retest reliability of the test and the separate
items were determined by calculating intraclass correlation
coefficient (ICC) with a random effect ANOVA model. An
ICC value of less than 0.40 was considered poor; an ICC
value between 0.40 and 0.80 was considered fair and an
ICC value greater than 0.80 was considered excellent.
Pearson correlation coefficients were used to determine
criterion validity; Spearman rank correlation coefficients
were used in case of non-normal distributions. For
differential validity, group differences were analyzed by
one-way analysis of variance followed by a Bonferroni post
hoc correction for multiple testing. P- values<0.05 (two-
tailed) were considered statistically significant.
Responsiveness was investigated by calculating the
standardized response mean. A score between 0.50 and
0.80 was considered moderate, and a score greater than
0.80 represents high responsiveness (Liang et al. 1990).
A Mann-Whitney test was used to test differences in
QMFT scores between the treated patients and the
untreated patients. A ROC curve was made by plotting
the true-positive rate (sensitivity) against the false-positive
rate (1-specificity). The area under the curve represents the
ability of the test to correctly discriminate between
improved and non-improved patients. This area ranges
from 0.5 (no discriminating ability) to 1.0 (perfect
discriminating ability).
Statisticalanalysiswasperformed using SPSSversion15.0.
Results
Study population
Clinical characteristics of the 91 patients enrolled in the
study are shown in Table 1. Nineteen patients were younger
than 18 years. The mean QMFT score at baseline
assessment was 36.9±16.6 (median 38.5, range 3 to 64),
on a possible score range from 0 to 64.
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The internal consistency of the QMFT was excellent:
Cronbach’s α was 0.94. There were no substantial floor
and ceiling effects: none of the patients reached the lowest
possible score, and only two of the patients reached the
highest possible score of 64. Both patients were diagnosed
presymptomatically.
The intraclass correlation coefficient for intrarater
reliability was 0.95 for the total scale. The ICCs for the
separate items of the scale ranged from 0.78 to 0.98. The
intraclass correlation coefficient for interrater reliability
was 0.91 for the total test. The ICCs for the separate items
of the scale ranged from 0.76 to 0.98.
The intraclass correlation coefficient for test-retest
reliability was 0.98 for the total test. The ICCs for the
separate items of the scale ranged from 0.84 to 1.00.
Validity
The total QMFT score correlated strongly with the strength
sum scores of proximal muscle groups assessed by MMT
and HHD (rs (MMT)=0.89 (p<0.001), rs(HHD)=0.81, (p<
0.01)). In sharp contrast, much lower correlations were
found between the QMFT and strength sum scores of other
muscle groups (rs(MMT)=0.05 (p=0.33), rs(HHD)=0.33
(p<0.01)) (Fig. 1).
Differentialvalidity wassupported by significantdifferences
between the three groups with different severities of disease (F
(2,84)=66.29, p<0.001). Mean QMFT scores significantly
decreased with the ability to walk: scores were highest in the
group that was fully ambulant (47.1±10.7, p<0.01), followed
by those for patients who were able to walk with aids (32.4±
11.0, p<0.01), and those for patients who were completely
wheelchair bound (16.6±10.6, p<0.01) (Fig. 2).
Responsiveness
Responsiveness was tested in 41 patients (18 treated; 23
untreated). Median age of the 18 patients that received
recombinant human alpha-glucosidase was 51.5 years
(range 5 to 76 years). Eight of these patients were
wheelchair bound, and ten patients were dependent on
ventilation. Median age of the 23 untreated patients was
52.1 years (range 34 to 72 years). Two patients were
wheelchair bound, and three used ventilation.
The QMFT scores of the treated patients (median change
4.15) showed a significant difference over one year period
comparedtotheQMFTscoresoftheuntreatedpatients(median
change0),(p<0.01).Thestandardizedresponsemeanwashigh
(0.81). Fig. 3 shows the ROC curve of the Quick Motor
Function Test with an area under the curve of 0.88 (p<0.05).
Discussion
This study shows that the Quick Motor Function Test is a
reliable and valid test for assessing motor function in
patients with Pompe disease. It is the first muscle function
test designed and validated specifically for Pompe patients.
The test had good psychometric properties, including good
internal consistency, and good intrarater and interrater
reliabilities over the entire test and the separate items. The
QMFT score strongly correlated with proximal muscle
strength as measured by HHD and MMT, and significantly
differentiated between patients with different levels of
mobility. The test was evaluated in patients between 5 and
76 years of age, and was easy and quick to administer.
According to the World Health Organization, assessment
of health should have a multi-dimensional approach. The
International Classification of Functioning, Disability and
Health (ICF) (World Health Organization 2001) provides
such an interdisciplinary framework and measures conse-
quences of disease in three domains: impairments of body
functions and body structures, activity limitations (individ-
ual level), and participation restrictions (societal level).
In Pompe disease, the approach towards evaluating
disease severity and effect of treatment has become
increasingly multi-dimensional over the past years. Mea-
surement tools have been designed and validated for their
use in Pompe patients. Currently, a battery of tests is used in
the long-term follow-up of Pompe patients. For example,
muscle strength, pulmonary function tests, echocardiogra-
phy, timed tests and the 6-minute walk test are used to
evaluate disease consequences and effect of treatment on
the level of body functions and body structures. The Pompe
Pediatric Evaluation of Disability Inventory (Pompe PEDI),
SF-36, and the Rotterdam Handicap Scale are used to
assess the level of participation restrictions and quality of
Table 1 Clinical characteristics of the 91 study patients
Sex (m/f) 52/39
Age (median) 46.3 years (range 5–76 y)
Age groups Number of patients
5-20 years 19
21-40 years 17
41-60 years 36
61-80 years 19
Motor status % of patients
Wheelchair bound 23
Using assistive devices 18
Fully ambulant 59
Respiratory status % of patients
Ventilation use 29.7
No ventilation 70.3
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tations on an individual level is currently lacking.
In clinical practice, muscle strength tests have often been
applied to assess muscle function. However, although
closely related, muscle strength and muscle function
represent two different entities of the muscle system, and
correspond to different levels of the ICF (World Health
Organization 2001). Both parameters should therefore be
evaluated separately by valid and reliable assessment tools.
In a recent placebo-controlled clinical trial in 90 juvenile
and adult patients with Pompe disease, primary outcome
measures were the 6 minute walk test (distance walked in 6
minutes), and Forced Vital Capacity in seated position (van
der Ploeg et al. 2010). Muscle function was not assessed,
because a reliable motor function test validated for Pompe
disease did not exist. Although it would have been possible
to use scales that were designed for other neuromuscular
disorders (Russell et al. 1989; Main et al. 2003; Scott et al.
1982; Lovell et al. 1999; Berard et al. 2005) or a composite
disease severity score that covers various domains of the
ICF, as developed by Lue et al. for Duchenne Muscular
Dystrophy (Lue et al. 2006), none of these scales were
validated for Pompe disease. Some were designed for
children, while Pompe disease affects all age groups. Our
study demonstrates that the QMFT can be used in both
children and adults, with different levels of disease severity.
Fig. 3 Receiver operating characteristic (ROC) curve to determine the
responsiveness of the Quick Motor Function Test (QMFT), with
clinical judgment as the external factor. Sensitivity was defined by
dividing the number of patients, who had been identified by the
QMFT to have changed, by the number of patients who had truly
undergone change as based on the judgment of two physicians.
Specificity was defined as the number of patients who had been
identified by the QMFT to not have changed, divided by the number
of patients who had not changed, based on the judgment of the same
physicians
Fig. 2 Mean scores (95% CI) on the Quick Motor Function Test of
the patients related to three grades of disease severity
Fig. 1 Relationshipofthe QMFT
score to manual muscle testing: a.
sumscore of proximal muscle
groups, b. sumscore of other
muscle groups
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to perform. The test takes approximately 15 minutes, does
not require specialized equipment, and can be performed by
a physician in a clinical setting. As opposed to other scales,
that frequently need to be performed by a physical
therapist. It is a practical tool that can be used in all
patients including those who are confined to a wheelchair
or dependent on artificial ventilation. The overall respon-
siveness of the QMFT appears to be good: the test
accurately detected change when it had occurred and
remained stable when no change had occurred. It also
discriminated between varying levels of disease. This
indicates that the QMFT can serve as a tool to estimate
disease severity, but also as a longitudinal assessment tool
to detect changes in motor function over time. This is
useful, as the emergence of new treatment modalities such
as enzyme replacement therapy and possibly chaperone
therapy will make the (long-term) evaluation of therapeutic
effects essential.
Four issues need further attention. First, while respon-
siveness to change, which was assessed in a subgroup of 18
treated and 23 untreated patients, showed promising results,
it is recommended to perform a large scale empirical study.
The current study was insufficient to demonstrate whether the
changes observed over time were related to enzyme replace-
menttherapyornot.Second,thetestwasvalidatedforpatients
between 5 and 76 years of age. In the youngest and oldest
patients, motor development and age-related motor limitation
might have interfered with the test results. Therefore,
reference values for age should be obtained. Third, to ensure
tester reliability we recommend annual recertification of the
physicians who perform the QMFT. Fourth, the present study
validated the QMFT in Pompe patients, but the test may also
be useful for other neuromuscular disorders, especially those
with proximal muscle weakness.
In conclusion, this study shows that the Quick Motor
Function Test has good psychometric properties and
excellent clinical utility. Our findings indicate that this test
can be used to assess motor function and response to
treatment in children and adults with different levels of
disease severity. The applicability of the test for other
neuromuscular disorders deserves further investigation.
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